# ELOQUENT - 2 (NCT01239797)

> Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01239797
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Lymphoma; Multiple Myeloma
- Interventions: Lenalidomide; Dexamethasone; Dexamethasone (Oral); Dexamethasone (IV); Elotuzumab (BMS-901608; HuLuc63)
- Enrollment: 646
- Primary outcome: Median Progression Free Survival (PFS)
- Primary outcome: Objective Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=eloquent-2-nct01239797